Tezacaftor and ivacaftor combination therapy for treating cystic fibrosis with the F508del mutation [ID1303]
Discontinued
Reference number: GID-TA10277
The company, Vertex Pharmaceuticals, has not provided an evidence submission for this appraisal. Therefore, we are suspending the appraisal whilst we consider the next steps. Consequently the discussion of this appraisal at the committee meeting on the 8 November 2018 has been cancelled. We will update you on our progress and next steps as soon as possible.